Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment Forecast

Diagnostics & Research is Zen Rated B and is the 52nd ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Price	Price Target	Upside/Downside	Consensus	Analysts	Fore. Revenue Growth	Fore. Earnings Growth	Forecast ROE	Forecast ROA
QGEN	QIAGEN NV	$9.38B	$42.20	$48.25	14.34%	Buy	4	5.30%	92.36%	18.01%	11.29%
ILMN	ILLUMINA INC	$12.12B	$76.51	$129.17	68.82%	Buy	12	2.36%	N/A	39.61%	14.91%
A	AGILENT TECHNOLOGIES INC	$30.35B	$106.46	$141.86	33.25%	Buy	7	4.41%	17.77%	31.32%	15.84%
WAT	WATERS CORP	$20.31B	$341.83	$391.67	14.58%	Buy	12	5.57%	15.34%	52.28%	20.99%
MTD	METTLER TOLEDO INTERNATIONAL INC	$22.10B	$1,056.58	$1.30k	22.74%	Buy	5	3.62%	8.66%	-910.41%	35.65%
DHR	DANAHER CORP	$140.78B	$196.71	$251.92	28.07%	Strong Buy	13	4.90%	28.52%	13.27%	8.53%
CDNA	CAREDX INC	$839.11M	$15.07	$30.00	99.07%	Buy	5	7.08%	N/A	-1.91%	-1.48%
IDXX	IDEXX LABORATORIES INC	$38.34B	$471.38	$505.83	7.31%	Buy	6	7.20%	12.14%	87.58%	42.42%
LH	LABCORP HOLDINGS INC	$20.20B	$241.28	$273.55	13.37%	Strong Buy	11	5.28%	30.34%	22.28%	10.51%
DGX	QUEST DIAGNOSTICS INC	$19.80B	$177.32	$184.36	3.97%	Buy	14	4.52%	12.14%	20.16%	8.84%
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$5.98B	$116.89	$188.67	61.41%	Hold	12	-0.33%	613.75%	16.58%	7.62%
CSTL	CASTLE BIOSCIENCES INC	$550.61M	$19.31	$39.60	105.08%	Strong Buy	5	-2.78%	N/A	-8.26%	-7.09%
IQV	IQVIA HOLDINGS INC	$26.61B	$151.10	$226.93	50.18%	Strong Buy	14	4.89%	21.75%	43.86%	9.89%
SHC	SOTERA HEALTH CO	$3.43B	$12.10	$15.50	28.10%	Strong Buy	4	4.20%	195.65%	N/A	N/A
RVTY	REVVITY INC	$11.17B	$92.90	$124.46	33.97%	Strong Buy	11	5.10%	58.02%	9.75%	6.03%
MEDP	MEDPACE HOLDINGS INC	$8.69B	$302.25	$325.20	7.59%	Hold	5	3.52%	1.89%	77.69%	24.31%
MYGN	MYRIAD GENETICS INC	$651.03M	$7.13	$18.35	157.36%	Buy	10	4.79%	N/A	-0.52%	-0.36%
XGN	EXAGEN INC	$109.89M	$6.14	$7.50	22.15%	Strong Buy	2	15.74%	N/A	-43.15%	-9.21%
FONR	FONAR CORP	$81.01M	$12.30	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NTRA	NATERA INC	$20.46B	$151.36	$192.17	26.96%	Strong Buy	12	15.55%	N/A	3.22%	2.32%
FLGT	FULGENT GENETICS INC	$531.81M	$17.25	$16.00	-7.25%	Hold	1	10.03%	N/A	-4.98%	-4.62%
MYNZ	MAINZ BIOMED NV	$6.91M	$2.98	$14.00	369.80%	Strong Buy	1	N/A	N/A	-352.90%	-161.19%
TWST	TWIST BIOSCIENCE CORP	$2.25B	$37.71	$53.17	40.99%	Buy	6	17.29%	N/A	-13.21%	-9.90%
TMO	THERMO FISHER SCIENTIFIC INC	$158.41B	$419.89	$578.85	37.86%	Strong Buy	13	4.63%	23.02%	21.55%	10.98%
GH	GUARDANT HEALTH INC	$6.05B	$48.87	$57.00	16.64%	Strong Buy	15	17.28%	N/A	N/A	-19.17%
DRIO	DARIOHEALTH CORP	$30.05M	$0.72	$2.00	176.63%	Strong Buy	1	18.66%	N/A	N/A	N/A
NEO	NEOGENOMICS INC	$934.32M	$7.26	$13.36	83.98%	Buy	7	10.93%	N/A	2.22%	1.23%
ICLR	ICON PLC	$11.54B	$145.21	$201.60	38.83%	Buy	10	3.70%	21.80%	15.45%	8.78%
BDSX	BIODESIX INC	$76.78M	$0.53	$2.50	375.29%	Strong Buy	1	30.04%	N/A	-97.90%	-21.02%
ADVB	ADVANCED BIOMED INC	$41.33M	$1.91	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GRAL	GRAIL INC	$1.10B	$32.49	$26.00	-19.98%	Buy	2	13.37%	N/A	-11.21%	-9.41%
EXAS	EXACT SCIENCES CORP	$8.90B	$47.16	$67.78	43.72%	Strong Buy	18	10.78%	N/A	11.29%	4.74%
STIM	NEURONETICS INC	$293.53M	$4.46	$7.50	68.16%	Strong Buy	2	99.83%	N/A	-66.51%	-13.08%
OPK	OPKO HEALTH INC	$1.07B	$1.35	$2.63	94.44%	Buy	2	4.68%	N/A	-2.72%	-1.68%
APDN	APPLIED DNA SCIENCES INC	$1.00M	$0.91	N/A	N/A	N/A	N/A	-9.46%	N/A	N/A	N/A
LAB	STANDARD BIOTOOLS INC	$420.67M	$1.11	N/A	N/A	N/A	N/A	-3.00%	N/A	-13.26%	-10.21%
OCX	ONCOCYTE CORP	$88.66M	$3.10	$4.42	42.48%	Buy	3	N/A	N/A	N/A	-69.30%
PSNL	PERSONALIS INC	$340.70M	$3.86	$8.00	107.25%	Strong Buy	4	22.91%	N/A	-4.35%	-3.27%
RDNT	RADNET INC	$3.87B	$52.21	$69.75	33.60%	Strong Buy	4	5.34%	866.75%	5.63%	1.55%
NOTV	INOTIV INC	$67.06M	$1.98	N/A	N/A	N/A	N/A	5.15%	N/A	-3.19%	-0.70%
SERA	SERA PROGNOSTICS INC	$110.35M	$2.93	N/A	N/A	N/A	N/A	1,133.77%	N/A	N/A	N/A
ACRS	ACLARIS THERAPEUTICS INC	$148.93M	$1.38	$11.67	745.43%	Strong Buy	6	13.26%	N/A	-59.66%	-42.12%
NEOG	NEOGEN CORP	$1.12B	$5.15	$9.00	74.76%	Buy	2	0.33%	N/A	4.00%	2.63%
VNRX	VOLITIONRX LTD	$47.02M	$0.49	$3.75	670.02%	Strong Buy	2	N/A	N/A	N/A	N/A
TRIB	TRINITY BIOTECH PLC	$6.09M	$0.79	N/A	N/A	N/A	N/A	15.85%	N/A	N/A	-77.09%
PRPH	PROPHASE LABS INC	$13.53M	$0.32	N/A	N/A	N/A	N/A	109.24%	N/A	N/A	N/A
STRR	STAR EQUITY HOLDINGS INC	$7.21M	$2.25	N/A	N/A	N/A	N/A	N/A	N/A	-3.19%	-2.08%
MDXH	MDXHEALTH SA	$8.61M	$1.74	$6.00	244.83%	Strong Buy	1	20.55%	N/A	-71.14%	-6.71%
PRPO	PRECIPIO INC	$9.55M	$6.35	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MMA	MIXED MARTIAL ARTS GROUP LTD	$8.81M	$0.86	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BIAF	BIOAFFINITY TECHNOLOGIES INC	$8.67M	$0.48	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PMAX	POWELL MAX LTD	$5.88M	$0.40	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XWEL	XWELL INC	$4.10M	$0.78	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CHEK	CHECK-CAP LTD	$4.62M	$0.79	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNR	BURNING ROCK BIOTECH LTD	$29.63M	$2.87	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ISPC	ISPECIMEN INC	$3.20M	$1.28	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRE	PRENETICS GLOBAL LTD	$67.91M	$5.23	$9.00	72.08%	Strong Buy	1	N/A	N/A	-16.16%	-12.89%
NDRA	ENDRA LIFE SCIENCES INC	$4.05M	$7.20	$50.00	594.44%	Buy	1	N/A	N/A	-242.64%	-139.53%

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in May 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the #1 top diagnostic & research stock out of 58 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Qiagen Nv (NYSE:QGEN) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: C, Financials: B, and AI: C.

Qiagen Nv (NYSE:QGEN) has a Due Diligence Score of 23, which is -4 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates QGEN as a "A".

QGEN passed 9 out of 38 due diligence checks and has weak fundamentals. Qiagen Nv has seen its stock lose -1.42% over the past year, overperforming other diagnostic & research stocks by 24 percentage points.

Qiagen Nv has an average 1 year price target of $48.25, an upside of 14.34% from Qiagen Nv's current stock price of $42.20.

Qiagen Nv stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Qiagen Nv, 25% have issued a Strong Buy rating, 0% have issued a Buy, 75% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the #2 top diagnostic & research stock out of 58 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: B, Growth: A, Momentum: F, Sentiment: C, Safety: B, Financials: B, and AI: C.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 16, which is -11 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates ILMN as a "B".

ILMN passed 5 out of 33 due diligence checks and has weak fundamentals. Illumina has seen its stock lose -38.63% over the past year, underperforming other diagnostic & research stocks by -13 percentage points.

Illumina has an average 1 year price target of $129.17, an upside of 68.82% from Illumina's current stock price of $76.51.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Illumina, 33.33% have issued a Strong Buy rating, 8.33% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 8.33% have issued a Strong Sell.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) is the #3 top diagnostic & research stock out of 58 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Agilent Technologies (NYSE:A) is: Value: B, Growth: C, Momentum: D, Sentiment: C, Safety: A, Financials: B, and AI: B.

Agilent Technologies (NYSE:A) has a Due Diligence Score of 47, which is 20 points higher than the diagnostic & research industry average of 27.

A passed 17 out of 38 due diligence checks and has strong fundamentals. Agilent Technologies has seen its stock lose -23.24% over the past year, overperforming other diagnostic & research stocks by 2 percentage points.

Agilent Technologies has an average 1 year price target of $141.86, an upside of 33.25% from Agilent Technologies's current stock price of $106.46.

Agilent Technologies stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Agilent Technologies, 14.29% have issued a Strong Buy rating, 14.29% have issued a Buy, 71.43% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 5 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.3%, which is 1 percentage points higher than the diagnostic & research industry average of 0.59%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

2. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.68%, which is the same as the diagnostic & research industry average of 0.59%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 21.9% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.6%, which is the same as the diagnostic & research industry average of 0.59%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 33% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.32% in the last day, and up 0.1% over the last week. Icon was the among the top losers in the diagnostics & research industry, dropping -4.11% yesterday.

Icon shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, the company lowered its FY25 guidance.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 57, which is 39 points higher than the diagnostic & research industry average of 18. It passed 4 out of 7 valuation due diligence checks.

Icon's stock has dropped -51.86% in the past year. It has underperformed other stocks in the diagnostic & research industry by -26 percentage points.

2. Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International (NYSE:CRL) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Charles River Laboratories International has a valuation score of 14, which is -4 points higher than the diagnostic & research industry average of 18. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates CRL a Valuation Rating of "B".

Charles River Laboratories International's stock has dropped -49.77% in the past year. It has underperformed other stocks in the diagnostic & research industry by -24 percentage points.

3. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 14, which is -4 points higher than the diagnostic & research industry average of 18. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates QGEN a Valuation Rating of "B".

Qiagen Nv's stock has dropped -1.42% in the past year. It has overperformed other stocks in the diagnostic & research industry by 24 percentage points.

Are diagnostic & research stocks a good buy now?

51.22% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 26.52% over the next year.

2.33% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 6.98% of diagnostic & research stocks are rated B (Buy), 81.4% are rated C (Hold), 9.3% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 39.08x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.